发现频率
展开,展开
左下倾斜,左下倾斜
Novartis Financial Results–Q12024
Latest news
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy(IgAN)portfolio
Novartis presents latest Phase III Fabhalta ® (iptacopan)data inC3glomerulopathy(C3G)showing clinically meaningful and statistically significant35.1%proteinuria reduction vs.placebo
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR68 per share in cash
The burden of IgAN
Novartis in Society Integrated Report2023